1
|
Joseph L, Corbasson A, Manceau S, Khimoud D, Meunier B, Cheminet G, Lefrere F, Jannot AS, Lu E, Arlet JB. Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease. Br J Haematol 2023; 200:563-567. [PMID: 36354234 PMCID: PMC9877809 DOI: 10.1111/bjh.18547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 09/30/2022] [Accepted: 10/19/2022] [Indexed: 11/11/2022]
Abstract
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Collapse
Affiliation(s)
- Laure Joseph
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Anne Corbasson
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Sandra Manceau
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Djamal Khimoud
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Benoit Meunier
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Geoffrey Cheminet
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France
| | - François Lefrere
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Anne-Sophie Jannot
- Faculty of Medicine, Université de Paris Cité, Paris, France.,Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Estelle Lu
- Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Jean-Benoît Arlet
- Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.,Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France.,INSERM U1163, CNRS 8254, Institut IMAGINE, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
2
|
Belsky JA, Carroll WR, Feliciano A, Jacob SA. Side effects following COVID-19 vaccination in pediatric patients with sickle cell disease. Pediatr Blood Cancer 2023; 70:e30193. [PMID: 36583456 PMCID: PMC9880642 DOI: 10.1002/pbc.30193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/07/2022] [Accepted: 12/13/2022] [Indexed: 12/31/2022]
Abstract
Vulnerable patient populations have seen decreased rates of vaccination against SARS-CoV2-19 (COVID-19) due to hesitancies and distrust, magnified by a paucity of data for certain populations. The rate of COVID-19 vaccination in children with sickle cell disease (SCD) remains low despite the risk for severe complications, resulting in continued infections and hospitalizations from COVID-19. We sought to describe vaccine reactions, including vaso-occlusive crises, emergency department visits, and hospitalizations, in children with SCD. Our findings will start to provide the necessary vaccine side effect data to inform patients, caregivers, and clinicians considering the COVID-19 primary vaccination series.
Collapse
Affiliation(s)
- Jennifer A. Belsky
- Department of PediatricsIndiana University School of MedicineIndianapolisIndianaUSA,Division of Pediatric Hematology OncologyRiley Hospital for ChildrenIndianapolisIndianaUSA,Marian University College of Osteopathic MedicineIndianapolisIndianaUSA
| | | | - Anna Feliciano
- Department of PediatricsIndiana University School of MedicineIndianapolisIndianaUSA
| | - Seethal A. Jacob
- Department of PediatricsIndiana University School of MedicineIndianapolisIndianaUSA,Division of Pediatric Hematology OncologyRiley Hospital for ChildrenIndianapolisIndianaUSA,Center for Pediatric and Adolescent Comparative Effectiveness ResearchIndianapolisIndianaUSA
| |
Collapse
|
3
|
Ferreira de Matos C, Comont T, Castex MP, Lafaurie M, Walter O, Moulis G, Dion J, Cougoul P. Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review. Expert Rev Hematol 2022; 15:1045-1054. [PMID: 36412212 DOI: 10.1080/17474086.2022.2149488] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION Sickle cell disease (SCD) is the most frequent inherited disorder in the world. It is caused by a single amino acid mutation on the beta-globin chain, which lead to red blood cell deformation, haemolysis, and chronic inflammation. Clinical consequences are vaso-occlusives crisis, acute chest syndrome, thrombosis, infection, and chronic endothelial injury. AREAS COVERED Corticosteroids are an old therapeutic class, that are inexpensive and widely available, which can be administered in different forms. Their adverse effects are numerous and well-known. This class could appear to be useful in SCD treatment due to its anti-inflammatory effect. Moreover, corticosteroids remain an essential therapeutic class for many indications, besides SCD. Although specific adverse effects of corticosteroids have been suspected in SCD patients for decades, recent papers has reported strong evidence of specific and severe adverse effects in this population. Based on a literature review, we will discuss pathophysiological considerations, consequences, and practical use of corticosteroids in SCD. EXPERT OPINION High corticosteroid doses, for any indication , induce vaso-occlusive crises, acute chest syndrome, and re-hospitalization in patients with SCD. There is no evidence of any benefits of corticosteroid use in the SCD acute events. Prevention by hydroxyurea and/or red blood cell transfusion or exchange should be discussed when corticosteroid use is indispensable.
Collapse
Affiliation(s)
| | - Thibault Comont
- Internal Medicine Department, Toulouse University Hospital, Toulouse, France
| | - Marie-Pierre Castex
- Pediatric Oncology Immunology Hematology Unit, Children's University Hospital - Toulouse University Hospital, Toulouse, France
| | - Margaux Lafaurie
- CIC 1436, Team Pharmacologie en Population, Cohortes, Biobanques (PEPSS), Toulouse, France.,Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France
| | - Ondine Walter
- Internal Medicine Department, Toulouse University Hospital, Toulouse, France.,CIC 1436, Team Pharmacologie en Population, Cohortes, Biobanques (PEPSS), Toulouse, France
| | - Guillaume Moulis
- Internal Medicine Department, Toulouse University Hospital, Toulouse, France.,CIC 1436, Team Pharmacologie en Population, Cohortes, Biobanques (PEPSS), Toulouse, France
| | - Jérémie Dion
- Internal Medicine Department, Toulouse University Hospital, Toulouse, France
| | - Pierre Cougoul
- Internal Medicine Department, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
4
|
Zhang P, Wei M, Jing P, Li Z, Li J, Zhu F. COVID-19 in children: epidemic issues and candidate vaccines. Chin Med J (Engl) 2022; 135:1314-1324. [PMID: 35830254 PMCID: PMC9433085 DOI: 10.1097/cm9.0000000000002169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2021] [Indexed: 11/26/2022] Open
Abstract
ABSTRACT A large-scale vaccination of coronavirus disease-19 (COVID-19) in adults has been conducted for nearly a year, and there is a growing recognition that immunization for children is also essential. It has been months since emergency use of pediatric COVID-19 vaccine was approved, we reviewed the prevalence and transmission of COVID-19 in children. The prevalence of COVID-19 in children is reduced due to vaccination even in a Delta prevalent period, so an increase in the vaccination rate is needed in children. Although the precise role of children in the transmission requires more research to uncover, they likely played a significant role, according to the available literature. We also described four candidate COVID-19 vaccines for children on their safety and immunogenicity and the impact of severe acute respiratory syndrome coronavirus 2 variants on childhood vaccination. Safety issues on pediatric vaccines post-approval, like adverse events following immunization and adverse events of special interest require studies on long-term and effective regulatory mechanisms.
Collapse
Affiliation(s)
- Peng Zhang
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210009, China
| | - Mingwei Wei
- NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
| | - Pengfei Jing
- NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
| | - Zhuopei Li
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210009, China
| | - Jingxin Li
- NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
| | - Fengcai Zhu
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210009, China
- NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
- Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China
| |
Collapse
|